Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Arius Research, Inc.
U.S. patent issued to Arius Research for anti-CD63 antibody for cancer treatment
April 8th, 2006
Arius Research Inc. (ARI) announced that it has received notice from the United States Patent and Trademark Office that U.S. patent No. 7,009,040 was issued for Arius' lead anti-CD63 antibody, AR7BD-33-11A to treat cancer. Previously Arius announced that it had received a Notice of Allowance in October 2005. The patent covers the antibody molecule, various uses of the antibody, its derivatives, and a method for using it, and other similar antibodies, to treat cancers such as prostate and breast cancer. Arius has several additional patent applications pending that will continue to enhance the value of this and other important antibody assets. ...
Source: Law & Health Weekly (2006-04-08)
|
